

# 5-LOXIN<sup>®</sup> (AKBA) Boswellic Acid

5-LOXIN<sup>®</sup> is a new, patent-pending, clinically-proven<sup>†</sup> dietary supplement ingredient. In human studies, 5-LOXIN is proven to promote joint health and function and protect against collagen degradation, an important component of connective tissues.

## 5-LOXIN<sup>®</sup> Shows Improvement in Joint Comfort and Flexibility within 7 days!

- Boswellic acids are natural, selective 5-lipoxygenase inhibitors. There are six boswellic acids; however, AKBA is the most active
- 5-LOXIN provides a higher concentration of AKBA, standardized to 30%, while other Boswellic acid fractions contain only 2% - 3%
- In a recent human study, both 100mg and 250mg of 5-LOXIN daily provided improvement in joint comfort and mobility within 7 days<sup>†</sup>
- 5-LOXIN provided significant benefits in WOMAC, VAS and LFI standardized testing methodologies for joint health<sup>†</sup>
- 5-LOXIN positively impacted biological markers associated with joint and general health, including TNFa, CRP, and IL-6
- 5-LOXIN was shown to significantly inhibit matrix metalloproteinase (MMP-3), enzymes that break down cartilage, collagen and connective tissues
- 5-LOXIN is well-tolerated, easy on the stomach and supported by extensive safety data

5-LOXIN inhibits an enzyme called 5-lipoxygenase. Less well known than the COX-2 inhibitors, 5-LOX inhibitors follow a distinctly different pathway involved in the breakdown of arachidonic acid, without the potentially negative effects associated with COX-2. And 5-LOXIN is a selective, non-redox 5-LOX inhibitor, which means that its action is very targeted, not affecting other systems. 5-LOXIN's safety is supported by historic usage, published human studies, and extensive safety and toxicity studies.

## Developed at the Laila Impex Research Center

5-LOXIN<sup>®</sup> is presented in alliance with Laila Nutra, a division of Laila Impex, one of the leading producers of herbal extracts in India. The center is recognized by the Indian Government's Department of Scientific and Industrial Research (DSIR), is affiliated with numerous university Ph.D. programs, and actively collaborates with Georgetown University and the Ohio State University Medical Center.

\*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Sengupta et. al., A double blind, randomized, placebo controlled study of the efficacy and safety of 5-LOXIN for treatment of osteoarthritis of the knee Arthritis Research & Therapy 2008, 10: R85 doi:10.1186/ar2461

5-LOXIN<sup>®</sup> is presented in alliance with Laila Nutra, India



5-LOXIN<sup>®</sup>

**p.i. thomas & co. inc.**  
119 Headquarters Plaza  
Morristown, NJ 07960

Tel: (973) 984-0900  
Fax: (973) -984-5666  
e-mail: [info@plthomas.com](mailto:info@plthomas.com)  
[www.plthomas.com](http://www.plthomas.com)

All information is offered in good faith, with out guarantee or obligation for the accuracy or sufficiency thereof, or the result obtained, and is accepted at the users risk. Nothing herein shall be construed as a recommendation for uses which infringe valid patents or as extending license under valid patents. Users are advised to evaluate this and other ingredients for performance and stability for each application.